Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Injection site erythema, Injection site pain, Malaise, Myalgia
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest); Mild injection site redness; Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest)), INJECTION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest)), INJECTION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), INJECTION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest)), INJECTION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Patient had experienced events during the 2 days after COVID-19 vaccination, which occurred on Wednesday, 03-Jan-2024 and Thursday, 04-Jan-2024.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:Master case